Ryosuke Sato1, Mirela Vatic1, Guilherme Wesley Peixoto da Fonseca2, Stephan von Haehling3. 1. Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Str. 40, 37075, Gottingen, Germany. 2. Heart Institute (InCor), University of São Paulo Medical School, Sao Paulo, SP, Brazil. 3. German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Gottingen, Germany. stephan.von.haehling@med.uni-goettingen.de.
Abstract
PURPOSE OF REVIEW: Sarcopenia and frailty are common in patients with heart failure (HF) and are strongly associated with prognosis. This review aims to examine promising biomarkers that can guide physicians in identifying sarcopenia and frailty in HF. RECENT FINDINGS: Traditional biomarkers including C-reactive protein, aminotransaminase, myostatin, and urinary creatinine as well as novel biomarkers including microRNAs, suppression of tumorigenicity 2 (ST2), galectin-3, and procollagen type III N-terminal peptide may help in predicting the development of sarcopenia and frailty in HF patients. Among those biomarkers, aminotransferase, urinary creatinine, and ST2 predicted the prognosis in HF patients with sarcopenia and frailty. This review outlines the current knowledge of biomarkers that are considered promising for diagnosing sarcopenia and frailty in HF. The listed biomarkers might support the diagnosis, prognosis, and therapeutic decisions for sarcopenia and frailty in HF patients.
PURPOSE OF REVIEW: Sarcopenia and frailty are common in patients with heart failure (HF) and are strongly associated with prognosis. This review aims to examine promising biomarkers that can guide physicians in identifying sarcopenia and frailty in HF. RECENT FINDINGS: Traditional biomarkers including C-reactive protein, aminotransaminase, myostatin, and urinary creatinine as well as novel biomarkers including microRNAs, suppression of tumorigenicity 2 (ST2), galectin-3, and procollagen type III N-terminal peptide may help in predicting the development of sarcopenia and frailty in HF patients. Among those biomarkers, aminotransferase, urinary creatinine, and ST2 predicted the prognosis in HF patients with sarcopenia and frailty. This review outlines the current knowledge of biomarkers that are considered promising for diagnosing sarcopenia and frailty in HF. The listed biomarkers might support the diagnosis, prognosis, and therapeutic decisions for sarcopenia and frailty in HF patients.
Authors: Pooja Dewan; Alice Jackson; Pardeep S Jhund; Li Shen; João Pedro Ferreira; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray Journal: Eur J Heart Fail Date: 2020-04-30 Impact factor: 15.534
Authors: Cristiana Vitale; Ewa Jankowska; Loreena Hill; Massimo Piepoli; Wolfram Doehner; Stefan D Anker; Mitja Lainscak; Tiny Jaarsma; Piotr Ponikowski; Giuseppe M C Rosano; Petar Seferovic; Andrew J Coats Journal: Eur J Heart Fail Date: 2019-10-23 Impact factor: 15.534
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Theresa A McDonagh; Marco Metra; Marianna Adamo; Roy S Gardner; Andreas Baumbach; Michael Böhm; Haran Burri; Javed Butler; Jelena Čelutkienė; Ovidiu Chioncel; John G F Cleland; Andrew J S Coats; Maria G Crespo-Leiro; Dimitrios Farmakis; Martine Gilard; Stephane Heymans; Arno W Hoes; Tiny Jaarsma; Ewa A Jankowska; Mitja Lainscak; Carolyn S P Lam; Alexander R Lyon; John J V McMurray; Alexandre Mebazaa; Richard Mindham; Claudio Muneretto; Massimo Francesco Piepoli; Susanna Price; Giuseppe M C Rosano; Frank Ruschitzka; Anne Kathrine Skibelund Journal: Eur Heart J Date: 2021-09-21 Impact factor: 29.983
Authors: Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2014-02-05 Impact factor: 24.094